Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Posts Slight Rise in Q2 Revenues, Modest Profit

NEW YORK (GenomeWeb News) — Transgenomic yesterday said first-quarter revenues inched up 1.5 percent as R&D spending increased 7 percent and the company turned last year’s loss to a modest profit.     
 
Total receipts for the three months ended June 31 rose to $6.3 million from $6.2 million year over year.
 
Transgenomic CEO Craig Tuttle said in a statement that the company saw “substantial improvement” over the previous quarter, adding that molecular diagnostics sales grew by over $200,000 compared with the first quarter of 2006.
 
Instruments and consumables sales “met internal projections,” Tuttle said, but the company’s pharmaceutical research services segment fell short of expectations due to “timing issues with receiving samples from some of our key pharmaceutical partners.”
 
R&D spending dipped to $492,000 from $531,000 year over year.
 
Transgenomic said its net income was $226,000, compared to a loss of $383,000 in the year-ago period. The most recent quarter included a $900,000 gain from the sale of securities and $600,000 in restructuring charges.
 
Tuttle said the company expects to realize “the full impact” of ongoing consolidations and other cost-reduction efforts by the fourth quarter of 2007.
 
Tuttle also predicted “strong financial performance in our traditional mutation discovery tools business and substantial growth in our diagnostics laboratory business and pharmaceutical research services business.”
 
Transgenomic said it had around $7.9 million in cash and cash equivalents as of June 30.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.